MET Polyclonal Antibody, Cy7 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-20721R-Cy7 |
| Product Name | MET Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Met (c Met) |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4233 |
| Swiss Prot | P08581 |
| Subcellular location | Secreted, Cell membrane |
| Synonyms | AUTS9; c met; cmet; c-Met; D249; Hepatocyte growth factor receptor; Hepatocyte growth factor receptor Precursor; HGF; HGF receptor; HGF SF receptor; HGF/SF receptor; HGFR; MET; Met proto oncogene tyrosine kinase; Met proto-oncogene (hepatocyte growth factor receptor); Met proto-oncogene; Met protooncogene; MET_HUMAN; Oncogene MET; Par4; Proto-oncogene c-Met; RCCP2; Renal cell carcinoma papillary 2 gene; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met. |
| Background | c-Met, a member of the tyrosine kinase superfamily, is the receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF). The mature c-Met protein is a disulfide-linked heterodimer with Mr=190 kDa composed of a heavily glycosylated alpha subunit that is completely extracellular in localization, and a beta subunit comprising an extracellular ligand binding domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Cells expressing c-Met include epithelial cells, endothelial cells, blood cells of various types, and glomerular mesenchymal cells. HGF/SF binding to c-Met stimulates receptor dimerization and the phosphorylation of numerous residues within the receptors cytoplasmic domain. Signaling proteins that are phosphorylated and/or localized in response to c-Met phosphorylation include: Grb2, Shc, Cbl, Crk, cortactin, paxillin, GAB1, PI3K, FAK, Src, Ras, ERK1 and 2, JNK, PLC gamma, AKT, and STAT3. HGF/SF stimulation of c-Met expressing cells enhances proliferation, migration, morphogenesis, and protease synthesis, characteristics that are associated with invasive cell phenotype. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid, kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing. |
| Application Dilution | |
| WB | 1:300-5000 |
Frequently asked questions
Which applications is MET Polyclonal Antibody, Cy7 Conjugated (bs-20721R-Cy7) validated for, and at what dilution?
bs-20721R-Cy7 is validated for WB (1:300-5000). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-20721R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise MET Polyclonal Antibody, Cy7 Conjugated (bs-20721R-Cy7)?
KLH conjugated synthetic peptide derived from human Met (c Met)
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-20721R-Cy7)?
Cy7 on bs-20721R-Cy7: excitation / emission 743nm/767nm.